| Drug General Information |
| Drug ID |
D02EIB
|
| Former ID |
DNC008940
|
| Drug Name |
4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H19NO2
|
| Canonical SMILES |
C1CNCCC12C=C(C3=CC=CC=C3O2)C4=CC=C(C=C4)O
|
| InChI |
1S/C19H19NO2/c21-15-7-5-14(6-8-15)17-13-19(9-11-20-12-10-19)22-18-4-2-1-3-16(17)18/h1-8,13,20-21H,9-12H2
|
| InChIKey |
OZOVJRMTVPPLSS-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Kappa-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Delta-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
| Mu-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
| Potassium voltage-gated channel subfamily H member 2 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction
|
|
Estrogen signaling pathway
|
|
Morphine addiction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Enkephalin release
|
|
Opioid proenkephalin pathway
|
|
Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Peptide ligand-binding receptors
|
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
|
G alpha (i) signalling eventsR-HSA-1296072:Voltage gated Potassium channels
|
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
|
Peptide GPCRs
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
|
GPCR downstream signalingWP69:TCR Signaling Pathway
|
|
Opioid Signalling
|
|
GPCR downstream signalingWP706:SIDS Susceptibility Pathways
|
|
Hematopoietic Stem Cell Differentiation
|
|
Potassium Channels
|
| References |
| REF 1 | J Med Chem. 2008 Oct 9;51(19):5893-6. Epub 2008 Sep 13.Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). |
|---|
